Biora Therapeutics has reported over 25% oral bioavailability for its innovative BioJet™ platform, a swallowable autoinjector designed for the oral delivery of proteins, antibodies, and other biomolecules. The company, emerging from restructuring, is advancing its smaller ‘00’ sized BioJet device with a focus on achieving IND-readiness. CEO Adi Mohanty highlighted the platform’s rapid progress, emphasizing its potential to revolutionize drug delivery by providing a needle-free alternative for patients.

The significance of these findings lies in the comparative bioavailability achieved with the BioJet platform. In large animal models, including swine and non-human primates, the BioJet platform has demonstrated mean bioavailability exceeding 25% versus IV administration for both peptides and antibodies, with some antibodies reaching up to 50% bioavailability. This performance starkly contrasts with traditional subcutaneous injections, which typically offer around 50% bioavailability, and existing oral technologies that yield only 1-5%. The absence of safety-related issues in over 600 devices dosed during preclinical studies further underscores the platform’s potential for clinical application.

The takeaway for the field is the transformative potential of the BioJet technology in drug development timelines and therapeutic strategies. By enabling oral dosing of biomolecules that currently suffer from poor bioavailability, Biora’s platform could facilitate the development of viable oral alternatives for injectable therapies, thereby enhancing patient convenience and compliance. Furthermore, the ability to leverage existing liquid drug formulations positions the BioJet platform as a competitive tool for both pipeline candidates and established biomolecule brands, potentially reshaping the landscape of drug delivery systems in the longevity and healthspan research domains.

Source: globenewswire.com